We demonstrate here, using the LDLR−/− mouse model of atherosclerosis, that pharmacological PTP1B systemic inhibition leads to protection against and reversal of atherosclerosis development, suggesting beneficial effects of PTP1B inhibition for the treatment of CVDs and reduction in CVD risk. This evidence concerns the gene LDLR and atherosclerosis.